Alvotech Closes $165M Public Offering and Private Placement, Underwriters Fully Exercise Option
ALVO sits 29% above its 52-week low of $2.94.
Summary
Alvotech has finalized its public offering and concurrent private placement, securing $165 million in gross proceeds. This financing includes the full exercise of the underwriters' option to purchase additional shares. The capital raise, which follows earlier announcements this week, provides significant funding for the company's biosimilar development and general corporate needs. This transaction results in approximately 11.2% dilution to existing shareholders.
At the time of this announcement, ALVO was trading at $3.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.94 to $9.94. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.